Trailing-twelve-month (TTM) revenue is $49.19 Billion with a year-over-year growth of +3.11%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $12,222,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-10-30 |
| Q4 FY2025Period ended 2025-12-31 | $12,503,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-11 |
| Q1 FY2026Period ended 2026-03-31 | $11,489,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-04-30 |
| Q2 FY2026Period ended 2026-06-30 | $12,973,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-07-30 |
| TTM revenue | $49,187,000,000 |
Current P/S: $130,181,908,300 market capitalization ÷ $49,187,000,000 TTM revenue = 2.65x.
Market capitalization source: FMP quote. Quote observed 2026-09-15T20:00:02.000Z. Latest revenue period ended 2026-06-30.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-30): $12.97B.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-16T00:15:33.408Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Abecma | N/A | $164M | $388M | $472M | $406M | $427M |
| Abraxane | $1.2B | $1.2B | $811M |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20202020-12-31 · USD | FY20212021-12-31 · USD | FY20222022-12-31 · USD | FY20232023-12-31 · USD | FY20242024-12-31 · USD | FY20252025-12-31 · USD |
|---|---|---|---|---|---|---|
| Europe | $9.9B | $10.7B | $13.5B | N/A | N/A | N/A |
| Other Region | $631M | $852M | $834M |
$49.19B
$49.19 Billion
+3.11%
vs. $47.70B a year ago (TTM)
+2.08%
5 Year compound annual growth rate
1 Year
+3.11%
3 Year
+2.87%
5 Year
+2.08%
10 Year
+10.81%
15 Year
+6.06%
20 Year
+4.78%
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $48.20B | ($105.00M) | (0.22%) |
| 2024 | $48.30B | +$3.29B | +7.32% |
| 2023 | $45.01B | ($1.15B) | (2.50%) |
| 2022 | $46.16B | ($226.00M) | (0.49%) |
| 2021 | $46.38B | +$3.87B | +9.09% |
| 2020 |
TTM Growth
+3.11%
3-Year CAGR
+2.87%
5-Year CAGR
+2.08%
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 40 comparable quarters.
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-16T00:15:33.408Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $875M |
| $368M |
| Baraclude | $447M | N/A | N/A | N/A | N/A | N/A |
|---|
| Breyanzi | N/A | $87M | $182M | $364M | $747M | $1.4B |
|---|
| Camzyos | N/A | N/A | $24M | $231M | $602M | $1.1B |
|---|
| Cobenfy | N/A | N/A | N/A | N/A | $10M | $155M |
|---|
| Eliquis | $9.2B | $10.8B | $11.8B | $12.2B | $13.3B | $14.4B |
|---|
| Empliciti | $381M | N/A | N/A | N/A | N/A | N/A |
|---|
| Krazati | N/A | N/A | N/A | N/A | $126M | $205M |
|---|
| Mature Products And All Other | $1.3B | $1.9B | $1.7B | N/A | N/A | N/A |
|---|
| Opdivo | $7.0B | $7.5B | $8.2B | $9.0B | $9.3B | $10.0B |
|---|
| Opdivo Ovantig | N/A | N/A | N/A | N/A | N/A | $238M |
|---|
| Opdualag | N/A | N/A | $252M | $627M | $928M | $1.2B |
|---|
| Orencia | $3.2B | $3.3B | $3.5B | $3.6B | $3.7B | $3.7B |
|---|
| Other Growth Brands | N/A | N/A | N/A | N/A | $1.6B | $1.9B |
|---|
| Other Legacy Brands | N/A | N/A | N/A | N/A | $925M | $798M |
|---|
| Pomalyst/Imnovid | $3.1B | $3.3B | $3.5B | $3.4B | $3.5B | $2.7B |
|---|
| Reblozyl | $274M | $551M | $717M | $1.0B | $1.8B | $2.3B |
|---|
| Revlimid | $12.1B | $12.8B | $10.0B | $6.1B | $5.8B | $3.0B |
|---|
| Sotyktu | N/A | N/A | $8M | $170M | $246M | $291M |
|---|
| Sprycel | $2.1B | $2.1B | $2.2B | $1.9B | $1.3B | $493M |
|---|
| Yervoy | $1.7B | $2.0B | $2.1B | $2.2B | $2.5B | $2.9B |
|---|
| Zeposia | $12M | $134M | $250M | $434M | $566M | $577M |
|---|
| $996M |
| $1.1B |
| Rest Of World | $5.5B | $5.6B | N/A | $12.8B | $13.2B | N/A |
|---|
| UNITED STATES | $26.6B | $29.2B | $31.8B | $31.6B | $34.1B | $33.3B |
|---|
| $42.52B |
| +$16.37B |
| +62.62% |
| 2019 | $26.14B | +$3.58B | +15.89% |
| 2018 | $22.56B | +$1.78B | +8.59% |
| 2017 | $20.78B | +$1.35B | +6.94% |
| 2016 | $19.43B | +$2.87B | +17.31% |
